Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Victoria M. Chia"'
Autor:
Hil Hsu, Shivani Aggarwal, Archana Balan, Biagio Ricciuti, Jacklynn V. Egger, Michele LeNoue-Newton, Marilyn Elaine Holt, Jocelyn Lee, Victoria M. Chia, Emily Chan, Marko Rehn, Xuena Wang, Christine M. Lovly, Gregory J. Riely, Mark M. Awad, Valsamo Anagnostou
Publikováno v:
Journal of Clinical Oncology. 41:41-41
41 Background: KRAS mutation accounts for ~37% of colorectal cancer (CRC), with KRAS G12C occurring in ~3% of CRC tumors. KRAS G12C mutation is associated with poorer prognosis in terms of real-world progression-free survival (rwPFS) and overall surv
Autor:
Christine Szekely, Dawn C. Buse, Victoria M. Chia, Alice R. Pressman, Alexandra B. Scott, Richard B. Lipton, Walter F. Stewart, Alice Jacobson, Shruti Vaidya
Publikováno v:
Headache
Objective To characterize patients who utilize services for migraine in a large integrated health care network, and describe patterns of care and utilization. Background Within health care systems, migraine is a common reason for seeking primary and
Autor:
Paul Muntner, Michael E. Farkouh, Emily C. McKinley, Robert Urman, Robert S. Rosenson, Victoria M. Chia, Christine Lay, Lisandro D. Colantonio, Ligong Chen
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-13 (2021)
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-13 (2021)
Background Migraine has been associated with cardiovascular disease (CVD) events among middle-aged adults. The objective of this study was to determine the risk for ischemic stroke and coronary heart disease (CHD) events among older adults with versu
Autor:
Alina Bogdanov, Lauren Fischer, Victoria M. Chia, Christine Szekely, Robert Urman, Lee Kallenbach, Soeren Rasmussen, Mark Bensink
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world
Autor:
Victoria M. Chia, Gataree Ngarmchamnanrith, Huakang Tu, Hil Hsu, Alexander I. Spira, Xuena Wang, Shivani Aggarwal, Gillis Carrigan, Jhanelle E. Gray
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 159
Introduction The KRAS p.G12C mutation, prevalent in non–small-cell lung cancer (NSCLC), has only recently become a viable target. Here we present results of the largest retrospective observational study analyzing KRAS p.G12C in patients with advanc
Publikováno v:
Journal of Clinical Oncology. 40:e21048-e21048
e21048 Background: KRAS p.G12C mutation accounts for ̃13% of non-squamous NSCLCs and recently became a druggable target. Prior standard of care (SOC) treatment options have been limited to checkpoint inhibitors and chemotherapies as a monotherapy or
Autor:
Guiandre Joseph, Jessica Choudhry, Jacqueline Wright, Deborah Arrindell, Victoria M. Chia, William Kormany, Janet Franklin, Anthony S. Stein, Hamid R. Amouzadeh, Mandy Parson
Publikováno v:
Drug Safety
Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children wit
Publikováno v:
Principles and Practice of Clinical Trials ISBN: 9783319526775
Principles and Practice of Clinical Trials
Principles and Practice of Clinical Trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e21500273d7f4eeaef1b273d6cbd6158
https://doi.org/10.1007/978-3-319-52677-5_69-1
https://doi.org/10.1007/978-3-319-52677-5_69-1
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
Background: Better understanding of migraine treatment in US clinical practice could be facilitated by availability of Migraine Disability Assessment (MIDAS) questionnaire results collected in routine care. We present results for migraine patients wi
Publikováno v:
Headache
Objective To estimate the baseline rates of vascular events among people with migraine. Background Several novel medications that target the calcitonin gene‐related peptide (CGRP) pathway are approved to treat people with migraine. Given that the C